References
- Boyle P, Autier P, Bartelink H et al. European code against cancer and scientific justification: third version. Ann. Oncol.14, 973–1005 (2003).
- Boyle P, d’Onofrio A, Maisonneuve P et al. Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? Ann. Oncol.14, 1312–1325 (2003).
- Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18(3), 581–592 (2007).
- Bonelli L. Colorectal carcinoma: is screening possible? Tech. Coloproctol.8(S2), S267–S272 (2004).
- DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease. Ann. Surg. Oncol.13(1), 12–30 (2006).
- Gallo A, Cha C. Updates on esophageal and gastric cancers. World J. Gastroenterol.12, 3237–3242 (2006).
- Ebert MP, Malfertheiner P. Pathogenesis of sporadic and familial gastric cancer: implications for clinical management and cancer prevention. Aliment. Pharmacol. Ther.16, 1059–1066 (2002).
- Wong BC, Lam SK, Wong WM et al.Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA14, 187–194 (2004).
- Broutet N, Plebani M, Sakarovitch C et al. Pepsinogen A, pepsinogen C, and gastrin as markers of atrohpic chronic gastritis in European dyspeptics. Br. J. Cancer88, 1239–1247 (2003).
- Ebert MP, Krüger S, Fogeron ML et al. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics5, 1693–1704 (2005).
- Ryu JW, Kim HJ, Lee YS et al. The proteomics approach to find biomarkers in gastric cancer. J. Korean Med. Sci.18, 505–509 (2003).
- Nishigaki R, Osaki M, Hiratsuka M et al. Proteomic identification of differentially-expressed genes in human gastric carcinomas. Proteomics5, 3205–3213 (2005).
- Melle C, Ernst G, Schimmel B et al. Characterization of pepsinogen C as a potential biomarker for gastric cancer using a histo-proteomic approach. J. Proteome Res.4, 1799–1804 (2005).
- Ebert MP, Meuer J, Wiemer JC et al. Identification of gastric cancer patients by serum protein profiling. J. Proteome Res.3, 1261–1266 (2004).
- Ebert MP, Niemeyer D, Deininger SO et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J. Proteome Res.5(9), 2152–2158 (2006).
- Ogata Y, Hepplmann CJ, Charlesworth MC et al. Elevated levels of phosphorylated fibrinogen-α-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J. Proteome Res.5(12), 3318–3325 (2006).
- Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol.3, 230–240 (2006).
- McCulloch P, Nieuwenhuizen W, Douglas J, Lowe GD, George WD. Coagulation disturbances in cancer of the breast and colon measured with specific monoclonal antibody enzyme immunoassay for fibrin–fibrinogen degradation products. Haemostasis20(2), 73–80 (1990).
- de Stefano V, Gugliotta L, Mazzucconi MG, Leone G, Mandelli F. Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto. Blood81(9), 2468–2469 (1993).
- Jemal A, Murray T, Ward E et al. Cancer statistics. CA Cancer J. Clin.55, 10–30 (2005).
- Albrethsen J, Bogebo R, Gammeltoft S et al. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1–3) in colon cancer serum and tumours: a biomarker study. BMC Cancer5, 8 (2005).
- Melle C, Ernst G, Schimmel B et al. Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology129, 66–73 (2005).
- Habermann JK, Roblick UJ, Luke BT et al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology131, 1020–1029 (2006).
- Ward DG, Suggett N, Cheng Y et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer94, 1898–1905 (2006).